Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.
Pulmonary arterial hypertension (PAH) is a rare debilitating disease characterized by an increase in pulmonary vascular resistance and progressive right ventricular failure. PAH may be primary or associated with other conditions such as collagen vascular disease, portal hypertension, and HIV. Intravenous epoprostenol improves the survival, exercise tolerance, hemodynamics, and quality of life in patients with PAH and is believed to work through multiple pathways including vasodilation, opposition of smooth-muscle hypertrophy, and inhibition of platelet aggregation. Common dose-limiting side effects are flushing, jaw pain, arthralgias, myalgias, and headache, which are attributed to the vasodilatory effects of epoprostenol. In clinical practice, patients often develop persistent rash that is distinct from the flushing associated with epoprostenol. The specific findings both on physical examination and on dermatopathology have not, however, been well described. This report describes the cutaneous and dermatopathologic findings of 12 patients who developed persistent rash while receiving long-term prostacyclin for PAH.
Myers
Sarah A
SA
Division of Dermatology, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA. myers011@mc.duke.edu
Ahearn
Gregory S
GS
Angelica Selim
M
M
Tapson
Victor F
VF
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology*; D011464:Epoprostenol / Q000009:adverse effects* / Q000627:therapeutic use; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008875:Middle Aged
D000959:Antihypertensive Agents; D011464:Epoprostenol